Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II double blind, multicenter, placebo controlled clinical study of MTX652 in patients with acute kidney injury (AKI) following cardiac surgery

Next Previous
Trial Profile

A Phase II double blind, multicenter, placebo controlled clinical study of MTX652 in patients with acute kidney injury (AKI) following cardiac surgery

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MTX 652 (Primary)
  • Indications Acute kidney injury
  • Focus Adverse reactions

Most Recent Events

  • 14 Dec 2023 According to a Mission Therapeutics media release, the US Food and Drug Administration has approved Investigational New Drug application for MTX652, to proceed with planned Phase II clinical trial in the US. The trial is expected to begin early next year, which will take place at multiple sites in North America and Europe.
  • 10 Jan 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top